MEDIA

All Pressreleases

Nanexa signs additional evaluation agreement

13 October, 2021

Nanexa AB today announced that the company has signed an additional so-called Material Transfer and Feasibility Study Agreement with one of the company’s existing customers, for evaluation of the PharmaShell® technology with a specific biological drug substance.

Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017

5 October, 2021

Nanexa AB today announces that the company has received a decision from Finansinspektionen (Sweden’s financial supervisory authority) to pay a penalty fee of SEK 1,000,000 regarding events that occurred in 2017.

Nanexa pauses NEX-18 study

24 September, 2021

Nanexa today announces that the inclusion of patients in the company’s phase I study with NEX-18, a depot formulation of 5-azacitidine, is paused due to moderate skin reactions at the injection site.

Nanexa receives orders for coating of sensors

3 September, 2021

Nanexa AB (publ) today announced that the company has received two orders for a substantial number of sensors for detection of radioactive isotopes of the noble gas xenon, from two American customers, totaling approximately SEK 1.7 million.

Nanexa publishes interim report for January – June 2021

20 August, 2021

First clinical study started and long-term financing secured

EPO communicates intention to grant Nanexa’s PharmaShell® patent in Europe

7 July, 2021

Nanexa AB is pleased to announce that the European Patent Office (EPO) has today issued a communication advising that it intends to grant a European patent relating to Nanexa’s PharmaShell® technology.

Nanexa raises approximately SEK 126.7 million in fully subscribed rights issue

Nanexa AB (publ) (”Nanexa” or the “Company”) today announces that the new share issue with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million before transaction costs (the “Rights Issue”) was fully subscribed. Approximately 16.6 percent of the Rights Issue was subscribed for through subscription commitments. In addition to the subscription through subscription commitments, approximately 40.2 percent was subscribed for by the use of subscription rights, and approximately 14.9 percent was subscribed for without subscription rights. The remaining part of the Rights Issue was subscribed for through guarantee commitments from the existing shareholder Rutger Arnhult via M2 Capital Management, and from external investors, including, amongst others, Health Runner and Modelio Equity.

Nanexa granted patent in South Korea

22 June, 2021

Nanexa AB (publ) today announced that the company has been granted a patent in South Korea relating to PharmaShell®-coated drugs.

Nanexa invites to webcast

14 June, 2021

Nanexa invites to a webcast where CEO David Westberg, Chairman of the Board Göran Ando and CFO Björn Svanström will provide an update of Nanexa and the purpose of the company’s upcoming rights issue.

Nanexa publishes EU growth prospectus in connection with fully guaranteed rights issue

11 June, 2021

On 7 June 2021, the board of directors of Nanexa AB (publ) (”Nanexa” or the ”Company”), based on the authorisation granted by the annual general meeting on 24 May 2021, resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million (the “Rights Issue”). In connection with the Rights Issue, Nanexa has prepared an EU growth prospectus which today has been approved by the Swedish Financial Supervisory Authority and published on the Company’s website www.nanexa.com.

The board of directors of Nanexa has resolved on a fully guaranteed rights issue of approximately SEK 126.7 million

7 June, 2021

The board of directors of Nanexa AB (publ) (”Nanexa” or the ”Company”) has today, based on the authorisation granted by the annual general meeting on 24 May 2021, resolved on a rights issue of shares with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million (the “Rights Issue”). The Rights Issue is fully covered by subscription undertakings and guarantee commitments. Certain existing shareholders have entered into subscription commitments, amongst others Rutger Arnhult via M2 Capital Management, Jan Petersen, Applied Ventures, and members of the Company’s board of directors and management team, including amongst others CEO David Westberg and chairman of the board Göran Ando. Furthermore, guarantee commitments have been provided by the existing shareholder Rutger Arnhult via M2 Capital Management, and external investors, including amongst others Health Runner and Modelio Equity. In addition, the board of directors may, based on the authorisation granted by the annual general meeting on 24 May 2021, resolve on an over-allotment issue of up to approximately SEK 23.5 million (the “Over-allotment Issue”), conditional upon the Rights Issue being oversubscribed. The purpose of the Rights Issue and the Over-allotment Issue (together the ”New Issues”) is to strengthen the Company’s financial position and to enable the planned clinical studies as well as other value creating activities supporting PharmaShell and the NEX projects.

Nanexa includes first patient in PharmaShell study

31 May, 2021

Nanexa AB (publ) today announces that the company has included the first patient in its first clinical study with PharmaShell®. A phase I study in Nanexa’s product project NEX-18.

Nanexa filing complaint of patent infringement

Nanexa AB (publ) today announces that the company has filed a complaint of patent infringement against the American company VitriVax Inc.

Bulletin from the Annual General Meeting of Nanexa

24 May, 2021

On May 24, 2021, the Annual General Meeting of Nanexa AB (publ) was held. Due to the risk of spreading of Covid-19 and the authorities’ regulations and advice, the Annual General Meeting was held only through advance voting (so-called postal voting) in accordance with temporary rules.

Nanexa granted patent in China

19 May, 2021

Nanexa AB (publ) today announced that the company has been granted a patent in China. This primary patent covers the manufacturing method, products that come out of it, and the use of PharmaShell®-coated drugs.

Interim report Q1 2021

6 May, 2021

“The development of Nanexa is continuing and at the beginning of the quarter we started our second proprietary product project, NEX-20. The choice of multiple myeloma as our second indication fits well with myelodysplastic syndrome (MDS) in NEX-18 and creates an interesting portfolio in haematological cancer. In 2021, we intend to identify another project, NEX-21, where PharmaShell® can create another unique product with major potential.” David Westberg, CEO Nanexa AB.

Nanexa launches clinical trial for NEX-18

28 April, 2021

Nanexa AB (publ) today announces that the company has started its first clinical study with PharmaShell®, a phase I study in Nanexa’s product project NEX-18, at the Karolinska University Hospital.

Nanexa announces second investment from Applied Ventures

15 April, 2021

On December 17, 2020, Nanexa AB (publ) (“Nanexa” or “the Company”) announced that the Company has entered into an investment agreement with Applied Ventures, LLC (“Applied Ventures”), the venture capital arm of Applied Materials, Inc., through which Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support Nanexa’s continued development and expansion. On January 12, 2021 Nanexa issued 686,492 shares, corresponding to an investment amount of USD 1m, and 3,558,278 warrants of the 2020/2021 series (the “Warrants”) to Applied Ventures. The Warrants carry the right, but not the obligation, for Applied Ventures to subscribe for up to 3,558,278 shares in Nanexa during two exercise periods, April 1-15, 2021 and December 1-15, 2021. Applied Ventures decides the number of Warrants to be exercised during each subscription period. The subscription price shall be equal to volume-weighted average price during the ten trading days immediately before the respective subscription period, less ten percent. In the first subscription period under the investment agreement, April 1-15, 2021, Applied Ventures has subscribed to 480,879 shares at SEK 8,95 per share, equaling SEK 4.3 million or around USD 0.5 million.

The covid situation at Uppsala University Hospital affects the start of the NEX-18 phase Ia study

12 April, 2021

Nanexa’s planned phase Ia study in the NEX-18 project was set to start on April 15. The clinic at Uppsala University hospital informed Nanexa last Friday that their staff need to be used in other departments for covid care, and therefore, the study can not be started as planned on the 15th. The company is in close contact with the clinic to find the quickest solution possible. On Nanexa’s other study site, at the Karolinska University Hospital in Huddinge, preparations are ongoing and the study is expected to start according to plan by end of April.

Nanexa recruits head of pharmaceutical development

15 March, 2021

Nanexa today announces that the company has recruited Jonas Fransson as head of pharmaceutical development as part of a strengthening of the organization. Jonas Fransson has long and solid experience in drug development and will start on May 1 this year and will be part of Nanexa’s management team.

Nanexa Year-end report 2020

18 February, 2021

“The fourth quarter of 2020 was one of the most eventful in Nanexa’s history. We received a GMP certificate for drug manufacturing and a clinical trial permit for our NEX-18 project. We signed a collaboration agreement with Applied Materials and an investment agreement with Applied Ventures and, after careful evaluation, we decided shortly after the end of the quarter to choose lenalidomide for our NEX-20 project.” David Westberg, CEO Nanexa

Nanexa announces the result of the use of warrants of series TO2

Nanexa AB (”Nanexa” or ”the Company”) today announced the result of the use of warrants of series TO2, which were issued in connection with the Company’s rights issue in February 2020. The result shows that a total of 2,956,588 warrants were used to subscribe for 2,956,588 new shares in the Company, corresponding to approximately 97.5 percent of the total number of issued warrants of series TO2.

Nanexa update 2021 – webcast

2 February, 2021

Nanexa invites to a webcast hosted by CEO David Westberg, Chairman Göran Ando, and board member Bengt Gustavsson, who will give an update and talk about their view on Nanexa and the current project portfolio.

Nanexa signs agreement with a European Biotech company for evaluation of PharmaShell®

28 January, 2021

Nanexa AB (publ) today announced that the company has signed an evaluation agreement, a so-called Material Transfer and Feasibility Study Agreement, with a non-disclosed European biotech company. The company is running a development project within the cardiovascular field, where PharmaShell®, as the drug delivery system, can enable an injectable product that releases the drug substance during 1-2 weeks.

Nanexa receives “Notice of Allowance” for patent application in Canada

26 January, 2021

Nanexa AB (publ) today announced that the company has received a so-called “Notice of Allowance” for a patent application in Canada. The patent application refers to PharmaShell® administered in every conceivable way, for example by parenteral injection, inhalation or by oral administration.

Nanexa chooses lenalidomide for the project NEX-20

13 January, 2021

Nanexa AB today announces that the company has chosen to develop a long-acting formulation of lenalidomide for the treatment of multiple myeloma. NEX-20 will be the company’s second own product project.

Nanexa completes the first part of the directed share issue to Applied Ventures

12 January, 2021

On December 17, 2020, Nanexa AB (publ) (“Nanexa” or “the Company”) announced that the Company has entered into an investment agreement with Applied Ventures, LLC (“Applied Ventures”) through which Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. Today, January 12, 2021, Nanexa’s Board of Directors has decided, with the support of the authorization received at the Annual General Meeting on June 2, 2020, to issue 686,492 shares and 3,558,278 warrants (the “Directed Issue”) to Applied Ventures. In accordance with the investment agreement, the subscription price for the shares in the Directed Issue has been set at the volume-weighted average price (“VWAP”) during the period December 22, 2020 through January 11, 2021 with a deduction of five percent, corresponding to SEK 11.99 per share.

Nanexa enters into an investment agreement with Applied Ventures of USD 3 million

17 December, 2020

Nanexa AB (publ) today announced that the company has entered into an investment agreement with Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., whereby Applied Ventures intends to invest up to USD 3 million in Nanexa during 2021 to support continued development and expansion. USD 1 million will be invested in January 2021 and additional investments of up to USD 2 million are planned later in 2021. The investment will be made through a directed issue to Applied Ventures of a mix of shares and share warrants decided upon by Nanexa with support of the authorization of the Annual General Meeting held on June 2, 2020 (the “Directed Issue”).

Nanexa signs Collaboration Agreement with Applied Materials, Inc.

Nanexa AB (publ) today announced that the company has entered into a collaboration agreement with the leading materials engineering solutions company Applied Materials, Inc. in order to establish a scaled-up GMP production site for ALD-coated pharmaceuticals located at Nanexa’s facilities in Uppsala.

Nanexa receives clinical trial approval for NEX-18

10 December, 2020

Nanexa AB (publ) today announced that the company has received permission to start the clinical trial for the drug candidate NEX-18 by the Swedish Medical Products Agency, Läkemedelsverket.

Nanexa in late stage partnering and investment negotiations with Applied Materials and Applied Ventures

27 November, 2020

Nanexa AB (publ) today announces that the company is in late stage negotiations about entering into a joint development agreement with the world leading materials engineering solutions company Applied Materials Inc.

Read more

Market Notice 76/20 – Information regarding Nanexa AB”s subscription options

24 March, 2020

The trading in Nanexa AB''s subscription options NANEXA TO2 will take place from April 1, 2020.

 

 

Please see the company''s webpage for the full terms of the subscription option.

Read more

Market Notice 74/20 – Last day of trading in Nanexa AB”s BTU

23 March, 2020

Last day of trading in the company''s paid subscribed unit, NANEXA BTU, is March 26, 2020.? 

Information about the paid subscribed unit: 
Shortname: NANEXA BTU 
ISIN: SE0013774619 
Orderbook-ID: 5U4E 
CFI: MCMUXR 
FISN: NANEXA/UT 4 AK + 2 TO 
Last day of trading: March 26, 

Read more

Market Notice 28/20 – Information regarding the rights issue from Nanexa AB

3 February, 2020

The last day of trading in the company"s shares NANEXA including the right to receive unit rights is February 5, 2020. The first day excluding the right to obtain the rights is February 6,

Read more

Marknadsmeddelande 23/19 – Sista dag för handel med teckningsoption i Nanexa AB

23 January, 2019

Sista dag för handel med bolagets teckningsoption serie TO 1, är den 30 januari 2019.